EA201891672A1 - Соединения и композиции для лечения криптоспоридиоза - Google Patents

Соединения и композиции для лечения криптоспоридиоза

Info

Publication number
EA201891672A1
EA201891672A1 EA201891672A EA201891672A EA201891672A1 EA 201891672 A1 EA201891672 A1 EA 201891672A1 EA 201891672 A EA201891672 A EA 201891672A EA 201891672 A EA201891672 A EA 201891672A EA 201891672 A1 EA201891672 A1 EA 201891672A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cryptosporidiosis
therapeutic agent
compositions
compounds
treatment
Prior art date
Application number
EA201891672A
Other languages
English (en)
Inventor
Тьерри Тидиан Диагана
Манджуната Уджини
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201891672A1 publication Critical patent/EA201891672A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к способу для лечения, профилактики, ингибирования, ослабления или устранения патологии и/или симптомологии криптоспоридиоза путем введения терапевтического средства, которое антагонизирует или модулирует активность фосфатидилинозитол-4-OH киназы (PI4K), липидной киназы простейших организмов криптоспоридий. В одном варианте осуществления терапевтическое средство представляет собой пиразоло[1,5-a]пиридиновое соединение формулы Iили его фармацевтически приемлемую соль, таутомер или стереоизомер, где переменные имеют значение, определенное в настоящей заявке.
EA201891672A 2016-01-21 2017-01-20 Соединения и композиции для лечения криптоспоридиоза EA201891672A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201600499R 2016-01-21
PCT/IB2017/050319 WO2017125898A1 (en) 2016-01-21 2017-01-20 Compounds and compositions for the treatment of cryptosporidiosis

Publications (1)

Publication Number Publication Date
EA201891672A1 true EA201891672A1 (ru) 2018-12-28

Family

ID=57944463

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891672A EA201891672A1 (ru) 2016-01-21 2017-01-20 Соединения и композиции для лечения криптоспоридиоза

Country Status (15)

Country Link
US (1) US20190030009A1 (ru)
EP (1) EP3405468A1 (ru)
JP (1) JP2019507122A (ru)
KR (1) KR20180102587A (ru)
CN (1) CN108495853A (ru)
AU (1) AU2017208948A1 (ru)
BR (1) BR112018014957A2 (ru)
CA (1) CA3012107A1 (ru)
CL (1) CL2018001881A1 (ru)
EA (1) EA201891672A1 (ru)
MX (1) MX2018008941A (ru)
PH (1) PH12018501489A1 (ru)
RU (1) RU2018130069A (ru)
TW (1) TW201728325A (ru)
WO (1) WO2017125898A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019301510B2 (en) * 2018-07-09 2024-06-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelminthic heterocyclic compounds
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
WO2021242581A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
CA3197199A1 (en) * 2020-10-14 2022-04-21 Novartis Ag Compounds and compositions for the treatment of cryptosporidiosis
CA3236894A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2013040527A1 (en) * 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
LT2925757T (lt) 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui

Also Published As

Publication number Publication date
AU2017208948A1 (en) 2018-08-09
KR20180102587A (ko) 2018-09-17
JP2019507122A (ja) 2019-03-14
TW201728325A (zh) 2017-08-16
WO2017125898A1 (en) 2017-07-27
PH12018501489A1 (en) 2019-03-25
CN108495853A (zh) 2018-09-04
CL2018001881A1 (es) 2018-08-17
RU2018130069A (ru) 2020-02-21
US20190030009A1 (en) 2019-01-31
MX2018008941A (es) 2018-09-03
BR112018014957A2 (pt) 2019-04-16
CA3012107A1 (en) 2017-07-27
EP3405468A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
EA201891672A1 (ru) Соединения и композиции для лечения криптоспоридиоза
SG11201907038WA (en) Quinazoline compound
MY193514A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
EA201790088A1 (ru) Ингибиторы syk
JOP20190257A1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
EA201690752A1 (ru) Ингибиторы g12c kras
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
NZ708593A (en) Novel pyrazole derivative
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
CY1121060T1 (el) Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
WO2019199667A3 (en) Pladienolide compounds and their use
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2019004200A (es) Terapia de combinacion.
PH12020551620A1 (en) Compositions for preventing or treating dry eye